These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1389 related articles for article (PubMed ID: 24439393)
21. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531 [TBL] [Abstract][Full Text] [Related]
22. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. van Burik JA Curr Opin Infect Dis; 2005 Dec; 18(6):479-83. PubMed ID: 16258319 [TBL] [Abstract][Full Text] [Related]
23. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021 [TBL] [Abstract][Full Text] [Related]
24. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954 [TBL] [Abstract][Full Text] [Related]
25. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378 [TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016 [TBL] [Abstract][Full Text] [Related]
30. Management of invasive mycoses in hematology patients: current approaches. Perfect JR Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104 [TBL] [Abstract][Full Text] [Related]
32. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. Salavert-Lletí M; Zaragoza-Crespo R Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284 [TBL] [Abstract][Full Text] [Related]
33. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ; Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073 [TBL] [Abstract][Full Text] [Related]
34. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol. Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873 [TBL] [Abstract][Full Text] [Related]
35. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251 [TBL] [Abstract][Full Text] [Related]
37. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice. Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680 [TBL] [Abstract][Full Text] [Related]
39. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis. Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]